Astrana Health, Inc. (NASDAQ:ASTH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $53.29.

Several equities analysts have recently weighed in on the company. Truist Financial reduced their price target on Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Stifel Nicolaus decreased their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Barclays started coverage on shares of Astrana Health in a research note on Tuesday. They set an “equal weight” rating and a $36.00 price objective for the company. Finally, Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd.

Astrana Health Trading Up 0.5 %

Shares of ASTH opened at $30.02 on Thursday. The firm has a market cap of $1.50 billion, a P/E ratio of 23.09, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The business has a 50-day moving average of $33.47 and a 200 day moving average of $41.49.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million for the quarter, compared to analysts’ expectations of $617.24 million. As a group, research analysts forecast that Astrana Health will post 1.15 EPS for the current year.

Institutional Trading of Astrana Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at about $1,164,000. Principal Financial Group Inc. bought a new position in shares of Astrana Health during the third quarter valued at about $13,383,000. Franklin Resources Inc. purchased a new position in shares of Astrana Health in the third quarter worth about $1,187,000. Geode Capital Management LLC bought a new stake in shares of Astrana Health in the 3rd quarter valued at about $58,995,000. Finally, HighTower Advisors LLC purchased a new stake in Astrana Health during the 3rd quarter valued at about $5,799,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.